Viridian Therapeutics Inc
1S1
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
252
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,294.30 | 32.90 | 0.36% |
| CAC 40 | 8,401.18 | 81.31 | 0.98% |
| DAX 40 | 26,569.99 | 202.75 | 0.77% |
| Dow JONES (US) | 53,559.99 | 9.45 | -0.02% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,584.79 | 19.05 | 0.07% |
| NASDAQ | 26,402.42 | 138.93 | -0.52% |
| Nikkei 225 | 66,405.56 | 273.59 | 0.41% |
| NZX 50 Index | 13,768.18 | 111.87 | -0.81% |
| S&P 500 | 7,711.76 | 19.23 | -0.25% |
| S&P/ASX 200 | 9,092.30 | 41.00 | 0.45% |
| SSE Composite Index | 3,952.18 | 4.39 | -0.11% |